Urology Times | News & Insights for Urologists & Health …
Urology PA describes patient response to prostate cancer support program. Kevin Zorn, MD, on variation in BPH procedure reimbursement across Canada. Raevti Bole, MD, on the role of …
Urology Times
Print media2 Commerce Dr, Cranbury, NJ 08512
ECLIPSE trial: 177Lu-PSMA-I&T extends rPFS vs hormone therapy …
1 day ago · “This is a significant accomplishment for Curium, demonstrating in the pivotal confirmatory ECLIPSE trial a statistically significant and clinically meaningful benefit of PSMA …
All News - Urology Times
Genetic testing in prostate cancer is increasing over time, data suggests. Hannah Clarke. November 11th 2024. “It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and …
FDA grants de novo clearance to Stone Clear device
1 day ago · The FDA has granted de novo clearance to the Stone Clear device, which delivers non-invasive ultrasound pulses to patients to facilitate passage of residual kidney stone …
Prostate Cancer | Urology News & Expert Insights
Nov 5, 2024 · NDA submitted for 3-month formulation of leuprolide mesylate for advanced prostate cancer. By Hannah Clarke. October 30th 2024. Healthy diet may lower risk of grade reclassification in patients with GG1 prostate cancer. …
Bladder Cancer | Urology News & Expert Insights
Nov 7, 2024 · Laura Bukavina, MD, on challenges faced by women with bladder cancer. Urology Times staff. September 4th 2024. “Even if they're postmenopausal, we remove the ovaries, which puts them at a higher risk for …
Advancements in Minimally Invasive Surgical Options …
Mar 31, 2022 · Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate affecting more than 40 million men in the United States with an associated prevalence that increases from 40% to 80% among …
Dr. Elterman discusses Rezum and Aquablation for …
Sep 10, 2021 · Dean Elterman, MD. At the 2021 American Urological Association annual meeting, Dean Elterman, MD, MSc, FRCSC, presented the studies “RezĹ«m water vapor therapy for large volume (≥80 mL) benign prostatic …
Long-term results of Rezum therapy for patients with …
Dec 23, 2021 · So, the retreatment rate for our small prostate cohort was 4.4%, which is in line with the results demonstrated from the original WATER clinical trial, 3 which also had a retreatment rate of 4.4%. For our large prostate …
5-year data sustain long-term effectiveness of …
Feb 28, 2022 · Regarding safety, the event rate at 3 months was 26% with Aquablation vs 42% with TURP (P = .0149). The rate of procedure-related ejaculatory dysfunction was 7% vs 25%, respectively (P = .0004). “Based on …